Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

35.78 -0.36 (-1.00%)
Streaming Delayed Price Updated: 12:07 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
31 32 Next >
Down 88%, Could Editas Medicine Be a Good Investment Now?
The past few years have been difficult ones, but shares of the gene editor are far more attractive now that a CRISPR medicine has passed regulatory hurdles. 
Via The Motley Fool
What Does It Mean for Investors if CRISPR Therapeutics Gets Bought Out in 2024?
An acquisition could be both a blessing and a curse for long-term investors. 
Via The Motley Fool
7 Healthcare Stocks Taking Medicine to the Next Level
With advances in technology potentially able to improve the human condition, these are the compelling healthcare stocks to consider. 
Via InvestorPlace
My 3 Highest-Conviction Growth Stocks to Buy in 2024
Simply put, these stocks inspire confidence. 
Via The Motley Fool
My 5 Top Growth Stocks to Buy Hand Over Fist for 2024
2024 could be a year of growth. 
Via The Motley Fool
Here's How Much $100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought This Week
These companies could stand out thanks to game-changing technology. 
Via The Motley Fool
2 Red Flags for Bluebird Bio Stock
The biotech's struggles may continue. 
Via The Motley Fool
3 Cathie Wood Stocks to Start Off Your New Year Right
The following stocks could deliver big gains over time. 
Via The Motley Fool
2 low-priced gene therapy stocks to speculate on
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe 
Via MarketBeat
Exposures Product Safety
The Ultimate Growth Stock to Buy With $1,000 Right Now
The stock, trading for about $60, has plenty of room to run. 
Via The Motley Fool
5 Innovative Stocks That Could Score a Win for Your Portfolio in 2024
You'll find exciting innovators across industries. 
Via The Motley Fool
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
2 Biotech Stocks With Huge Catalysts in 2024
Important clinical-trial readouts on the way could send these stocks soaring in early 2024. 
Via The Motley Fool
Gen Z’s Top Picks for 2024: 7 Trending Stocks Among Young Investors
Gen Z stocks include companies the generation prefers to invest in while capturing the emerging economic force they represent. 
Via InvestorPlace
Here's Why 2024 Could Be a Big Year for CRISPR Therapeutics
CRISPR Therapeutics' shares climbed considerably last year -- but more gains could be just ahead. 
Via The Motley Fool
3 Healthcare Stocks to Make You the Millionaire Next Door: 2024 Edition
Healthcare stocks tend to be more mature and reliable, but a handful of innovators offer massive long-term upside. 
Via InvestorPlace
Better Risky Investment: Bluebird Bio vs. Shiba Inu
Few investors dare to tread where the ice is known to be very thin. 
Via The Motley Fool
3 Biotech Stocks Set for Breakthroughs in 2024
With groundbreaking advancements in new medicine and science, 2024 holds a promising future for these biotech stocks. 
Via InvestorPlace
2 gene-editing stocks reshaping hereditary disease treatments
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal 
Via MarketBeat
3 No-Brainer Growth Stocks to Buy for Less Than $100
These businesses have promising futures and make for great investment options today. 
Via The Motley Fool
1 Cathie Wood Stock Worth Buying Hand Over Fist in 2024
Ark Invest holds a hefty position in this gene-editing stock. Risk-tolerant investors may want to take a page from the fund's playbook on this name. 
Via The Motley Fool
2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics
Curing rare inherited illnesses could be a lucrative business model. 
Via The Motley Fool
2023 in Review: Nvidia, Interest Rates, Taylor Swift
And a little bit of real estate insight. 
Via The Motley Fool
3 Stocks That Could Be Monster Winners in 2024
Don't be surprised if these three stocks take off in the new year. 
Via The Motley Fool
AI and Automation Leaders for 2024: 7 Stocks to Stay Ahead of the Robot Uprising
With the robotics revolution taking over multiple industries, investors have options. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
CRISPR Therapeutics sets sights on gene-editing cures for disease
On Dec. 8, 2023, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for 
Via MarketBeat
Exposures Product Safety
3 Top Stocks to Buy Hand Over Fist Before the End of 2023
These are ideal stocks to buy sooner rather than later. 
Via The Motley Fool
3 Healthcare Technology Stocks to Improve Lives in 2024
Healthcare technology is one of 2024's top investment trends, and investors looking for long-term upside should check out these top stocks. 
Via InvestorPlace
1 Green Flag and 1 Red Flag for Bluebird Bio Stock
The stock has been in the news lately. 
Via The Motley Fool
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.